Repurposed drugs hold immense potential to address unmet medical needs rapidly. Due to their established safety and efficacy profiles, these therapies can be brought to market more swiftly than new drugs. A coordinated European reimbursement guideline will ensure rapid and cost-effective patient benefit from these advancements.
To harness the massive potential of drug repurposing, the REPO4EU platform and consortium -with the support of the EU- propose the establishment of a Special Interest Group (SIG) to advocate for a Guideline from the European Commission setting out best practices for health-technology agencies across different countries to reimburse repurposed drugs at a price that ensures a fair and reasonable return on investment to enable the final stages of development and the necessary investments.
January 15 is the day. The event starts at 12 pm (local time) and will run through the afternoon until 6 pm.
HOW?
This is an open hybrid event so if it’s impossible for you to join in person, there will be an option to connect online. You just need to select this modality in the registration form.
By joining forces, we can ensure that repurposed drugs receive the attention and support they deserve, ultimately benefiting patients with innovative, effective, and affordable therapies. We look forward to your collaboration and contributions to this crucial initiative.
